Bear Stearns Upgrades CV Therapeutics

Analyst Akhtar Samad says the biopharmaceutical's angina drug Ranexa met its primary endpoint of statistically significant reduction in angina frequency

Bear Stearns upgrades CV Therapeutics (CVTX ) to peer perform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.